Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | CDC7 | O00311 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 8/20 | 0.43 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24216393 | 0.91 | HDAC6 (0.51) | HDAC6CDC7NAMPTTEKKDR | |
| SCHEMBL31535166 | 0.91 | HDAC6 (0.51) | HDAC6CDC7NAMPTTEKKDR | |
| SCHEMBL25351724 | 0.91 | HDAC6 (0.53) | HDAC6CDC7TEKKDRHDAC1 | |
| SCHEMBL24216687 | 0.89 | HDAC6 (0.51) | HDAC6CDC7TEKKDRHDAC1 | |
| SCHEMBL30409410 | 0.89 | HDAC6 (0.51) | HDAC6CDC7TEKKDRHDAC1 | |
| SCHEMBL25355685 | 0.89 | HDAC6 (0.49) | HDAC6CDC7TEKKDRHDAC1 | |
| SCHEMBL24215954 | 0.89 | HDAC6 (0.49) | HDAC6CDC7NAMPTTEKKDR | |
| SCHEMBL25353260 | 0.88 | HDAC6 (0.50) | HDAC6CDC7TEKKDRHDAC1 | |
| SCHEMBL25351400 | 0.88 | HDAC1 (0.42) | HDAC6CDC7HDAC1 | |
| SCHEMBL25350257 | 0.88 | HDAC6 (0.51) | HDAC6CDC7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885CDC7 1660/4885NAMPT 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.